Event InfoCategory Date and Time
- Wednesday, May 18, 2022
- 01:00 PM - 02:00 PM
- Paradise Lost: The Neurobiology of Child Abuse and Neglect
Charles Nemeroff MD PhD
- Matthew P. Nemeroff Endowed Chair, Department of Psychiatry & Behavioral Sciences
- Director, Institute for Early Life Adversity
- Research Professor, Department of Psychiatry & Behavioral Sciences
- The University of Texas at Austin, Dell Medical School
- School of Public Health / Psychiatric Institute (SPHPI)
- 1601 W. Taylor St.
- Chicago IL 60612
- Auditorium, Room 109
- Department of Psychiatry Education Team
- psych-education [at] uic.edu
In-person only, will not be live-streamed
Charles B. Nemeroff, MD, PhD is Professor and Chair of the Department of Psychiatry and Behavioral Sciences at the Dell Medical School, University of Texas at Austin. He also directs the Institute for Early Life Adversity Research within the department as part of the Mulva Clinic for the Neurosciences, and co-directs the Center for Psychedelic Research and Therapy. Prior to joining Dell Med, Dr. Nemeroff was chair of the Department of Psychiatry and Behavioral Sciences and clinical director of the Center on Aging at the University of Miami Miller School of Medicine in Miami, Florida. He received his medical degree and doctorate degrees in neurology from the University of North Carolina (UNC) School of Medicine.
Dr. Nemeroff has received a number of research and education awards including the Mrazek Award in Psychiatric Pharmacogenomics, Kempf Award in Psychobiology, the Samuel Hibbs Award, Research Mentoring Award, Judson Marmor Award and the Vestermark Award from the American Psychiatric Association (APA), the Mood Disorders Award, Bowis Award and Dean Award from the ACP and the Julius Axelrod Award for mentoring from the ACNP. He was elected to the National Academy of Medicine in 2002. He was also named Alumnus of the Year from the University of North Carolina and from the UNC Medical School. He received the Doctorate Honoris Causa from Maimonides University in Buenos Aires in 2015 and a Professor Honoris Causa from Favaloro University in Buenos Aires in 2021.
Dr. Nemeroff is a member of the APA Council on Research and Chairs both the APA Research Colloquium for Young Investigators and the APA Work Group on Biomarkers and Novel Treatments. His research is focused on the pathophysiology of mood and anxiety disorders with a focus on the role of child abuse and neglect as a major risk factor. He has also conducted research on the role of mood disorders as a risk factor for major medical disorders including heart disease, diabetes and cancer. He has published more than 1,100 research reports and reviews, and his research is currently supported by grants from the National Institutes of Health.
Dr. Nemeroff has also served on the Mental Health Advisory Council of National Institute of Mental Health and the Biomedical Research Council for NASA; is co-editor in chief (with Alan F. Schatzberg, MD) of the Textbook of Psychopharmacology, published by the APA Press and now in its Fifth Edition; and is the co-editor in chief of a new journal published by Elsevier, Personalized Medicine in Psychiatry. He is President of the Anxiety and Depression Association of America (ADAA).
Psychiatrists, Neurologists, and other affiliated professionals interested in mental health
To provide current information on research, treatment, and policy issues relating to psychiatry and its adjunct fields
- Discuss how genetic polymorphisms and epigenetics affect psychiatric disease vulnerability.
- Explain how a gene variation affects brain development and function so that the risk of a depressive episode or PTSD is increased.
- Describe how early life experience produces persistent CNS alterations and their implications.
The University of Illinois at Chicago (UIC) College of Medicine is accredited by the Accreditation Council for Continuing Medical Education ACCME) to provide continuing medical education for physicians.
The University of Illinois at Chicago (UIC) College of Medicine designates this live activity for a maximum of 1credit AMA PRA Category 1 credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Continuing Education Units (1) will be available for Social Workers and affiliated reciprocal agencies. Illinois Board License number 159-000112.
The Department of Psychiatry at the University of Illinois at Chicago is approved by the American Psychological Association to sponsor continuing education for psychologists. The Department of Psychiatry at the University of Illinois at Chicago maintains responsibility for this program and its content. This event is 1 credit hour continuing education.
No member of the planning committee for this activity have reported a relevant relationship with a commercial interest. There is no conflict of interest and nothing to disclose.
Dr. Nemeroff has disclosed providing consulting services for the following companies: AbbVie, ANeuroTech (division of Anima BV), Signant Health, Magstim, Inc., Navitor Pharmaceuticals, Inc., Intra-Cellular Therapies, Inc., EMA Wellness, Acadia Pharmaceuticals, Sage, BioXcel Therapeutics, Silo Pharma, XW Pharma, Neuritek, Engrail Therapeutics, Corcept Therapeutics Pharmaceuticals Company, SK Life Science, Alfasigma, Pasithea Therapeutic Corp., EcoR1, GoodCap Pharmaceuticals, Inc., Senseye ; owning stocks in the following companies: Xhale, Seattle Genetics, Antares, BI Gen Holdings, Inc., Corcept Therapeutics Pharmaceuticals Company, EMA Wellness, TRUUST Neuroimaging ; serving on the scientific advisory boards of the following entities: ANeuroTech (division of Anima BV), Brain and Behavior Research Foundation (BBRF), Anxiety and Depression Association of America (ADAA), Skyland Trail, Signant Health, Laureate Institute for Brain Research (LIBR), Inc., Magnolia CNS, Heading Health, TRUUST Neuroimaging, Pasithea Therapeutic Corp., Sage ; serving on the board of directors of the following entities: Gratitude America, ADAA, Xhale Smart, Inc., Lucy Scientific Discovery, Inc.; and holding the following patents: Method and devices for transdermal delivery of lithium (US 6,375,990B1) , Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2).